T among participants living in Peru (46.0 ), Brazil (37.8 ), and Ecuador (37.3 ), with lower prevalence among participants living in Thailand (6.4 ), South Africa (17.6 ), and the United States (27.1 ; P,0.001). Randomization group was not associated with HSV-2 prevalence at baseline (P = 0.44). In multivariable analysis, all factors remained significantly associated with HSV-2 prevalence with the
Idence of 6.1 per 100 person-years) and 60 were in the placebo group (incidence of 5.6 per 100 person-years). There was no significant difference in time to HSV-2 incidence among participants assigned to the FTC/TDF arm compared with those assigned to the placebo arm (HR 1.1, 95 CI: 0.8?.5; P = 0.64; Figure 2). Compared with participants in the placebo arm, there was also no difference in time to
Nt HSV-2 infection in iPrEx was receptive anal intercourse without a condom, a finding that has been reported in several studies of behavioral risk factors for HSV-2 acquisition in MSM. [18,19,20] The rectal mucosa and cervicovaginal mucosa may differ in their susceptibility to HSV-2 infection. Additionally, although oral dosing of tenofovir achieves drug concentrations that are 20?00 times higher
Nt HSV-2 infection in iPrEx was receptive anal intercourse without a condom, a finding that has been reported in several studies of behavioral risk factors for HSV-2 acquisition in MSM. [18,19,20] The rectal mucosa and cervicovaginal mucosa may differ in their susceptibility to HSV-2 infection. Additionally, although oral dosing of tenofovir achieves drug concentrations that are 20?00 times higher
Version; however, this finding was not confirmed by ulcers identified during STI examinations and may have included ulcers of nonherpetic etiologies. In contrast to the 51 reduction in HSV-2 incidence among women randomized to use a 1 tenofovir topical gel in CAPRISA 004, [9] our results suggest that tenofovir in daily oral FTC/TDF may reduce the occurrence of ulcers in individuals with HSV-2 in
Version; however, this finding was not confirmed by ulcers identified during STI examinations and may have included ulcers of nonherpetic etiologies. In contrast to the 51 reduction in HSV-2 incidence among women randomized to use a 1 tenofovir topical gel in CAPRISA 004, [9] our results suggest that tenofovir in daily oral FTC/TDF may reduce the occurrence of ulcers in individuals with HSV-2 in
D ,25 years (7.1 per 100 person-years) and the lowest rate among participants aged 40 years (1.6 per 100 person-years; P trend = 0.001). Country of residence was also associated with HSV-2 incidence, with theDaily Oral FTC/TDF PrEP and HSV-2 among MSMthere were 72 ulcer AEs classified as Grade 2 or above, with 43 participants (4.3 ) having 1 ulcer AE. Among the 72 ulcer AEs, 23 (31.9 ) were conf
D ,25 years (7.1 per 100 person-years) and the lowest rate among participants aged 40 years (1.6 per 100 person-years; P trend = 0.001). Country of residence was also associated with HSV-2 incidence, with theDaily Oral FTC/TDF PrEP and HSV-2 among MSMthere were 72 ulcer AEs classified as Grade 2 or above, with 43 participants (4.3 ) having 1 ulcer AE. Among the 72 ulcer AEs, 23 (31.9 ) were conf